- Home
- BGNE vs TEF Comparison
BGNE vs TEF Comparison
Compare BGNE & TEF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGNE
- TEF
- Stock Information
- Founded
- BGNE 2010
- TEF 1924
- Country
- BGNE Cayman Islands
- TEF Spain
- Employees
- BGNE N/A
- TEF N/A
- Industry
- BGNE Biotechnology: Pharmaceutical Preparations
- TEF Telecommunications Equipment
- Sector
- BGNE Health Care
- TEF Telecommunications
- Exchange
- BGNE Nasdaq
- TEF Nasdaq
- Market Cap
- BGNE 21.0B
- TEF 25.2B
- IPO Year
- BGNE 2016
- TEF 1987
- Fundamental
- Price
- BGNE $189.23
- TEF $4.41
- Analyst Decision
- BGNE Buy
- TEF
- Analyst Count
- BGNE 7
- TEF 0
- Target Price
- BGNE $247.07
- TEF N/A
- AVG Volume (30 Days)
- BGNE 281.8K
- TEF 601.1K
- Earning Date
- BGNE 11-12-2024
- TEF 11-07-2024
- Dividend Yield
- BGNE N/A
- TEF 7.30%
- EPS Growth
- BGNE N/A
- TEF N/A
- EPS
- BGNE N/A
- TEF N/A
- Revenue
- BGNE $3,351,304,621.00
- TEF $45,249,832,683.00
- Revenue This Year
- BGNE $969.39
- TEF $1.62
- Revenue Next Year
- BGNE $24.79
- TEF $0.01
- P/E Ratio
- BGNE N/A
- TEF N/A
- Revenue Growth
- BGNE 50.22
- TEF 2.55
- 52 Week Low
- BGNE $126.97
- TEF $3.82
- 52 Week High
- BGNE $248.16
- TEF $4.93
- Technical
- Relative Strength Index (RSI)
- BGNE 31.72
- TEF 36.94
- Support Level
- BGNE $189.60
- TEF $4.25
- Resistance Level
- BGNE $209.29
- TEF $4.70
- Average True Range (ATR)
- BGNE 6.42
- TEF 0.05
- MACD
- BGNE -2.10
- TEF -0.03
- Stochastic Oscillator
- BGNE 9.19
- TEF 34.44
About BGNE BeiGene Ltd.
BeiGene Ltd is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. BeiGene's key cancer treatments are BRUKINSA (zanubrutinib), Bruton's tyrosine kinase (BTK) inhibitor, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody. In addition, it has a diverse pipeline of novel therapeutics focusing on a range of malignancies, including AML, MDS, multiple myeloma, lung, gastrointestinal, breast, and gynecologic cancers. The Company operates in one segment: pharmaceutical products and is primarily located in the U.S. and the PRC. Key revenue is generated from the U.S.
About TEF Telefonica SA
Telefonica operates mobile and fixed networks in Spain (where it is the incumbent telephone operator), the UK, Germany, Brazil, and other Latin American countries like Colombia, Mexico, Argentina, and Chile. The company derives more than 30% of its revenue from Spain, close to 20% from Germany, and 20% from Brazil. Its UK operations are held through a joint venture with Virgin Media. For several years Telefonica has been simplifying its corporate structure by selling noncore assets.